InterPAD - DETAILS

Olaparib, 763113-22-0, AZD2281, Lynparza, AZD-2281, KU-0059436, AZD 2281, 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine, OLAPARIB cpd, 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one, KU-59436, UNII-WOH1JD9AR8, WOH1JD9AR8, Olaparib (AZD-2281), Olaparib (AZD2281, Ku-0059436), Olaparibum, Olaparib [USAN:INN], AZ2281, NSC-747856, AZD221, CHEBI:83766, 4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one, MFCD13185161, AZ-2281, KEYLYNK-010 COMPONENT OLAPARIB, KU59436, KU 59436, 4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One, 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one, NSC 747856, OLAPARIB COMPONENT OF KEYLYNK-010, OLAPARIB (MART.), OLAPARIB [MART.], Olaparib (DISCONTINUED), Olaparib [INN], (2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-, 1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-, 4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one, PIPERAZINE, 1-(CYCLOPROPYLCARBONYL)-4-(5-((3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL)-2-FLUOROBENZOYL)-, Olaparib (AZD2281; Ku-0059436), C24H23FN4O3, Olaparib (AZD2281), 4-(3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one, 4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one, Olaparib- Bio-X, Lynparza (TN), 09L, 1(2H)-PHTHALAZINONE, 4-((3-((4-(CYCLOPROPYLCARBONYL)-1-PIPERAZINYL)CARBONYL)-4-FLUOROPHENYL)METHYL)-, 4-((3-((4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL)CARBONYL)-4-FLUOROPHENYL)METHYL)PHTHALAZIN-1(2H)-ONE, 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one, 4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone; AZD 2281; KU 0059436; KU 59436; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine;, AZD2281(olaparib), OLAPARIB [USAN], OLAPARIB [JAN], OLAPARIB [MI], OLAPARIB [VANDF], OLAPARIB [WHO-DD], AZD-2281 (Olaparib), PARP inhibitor AZD2281, Olaparib (JAN/USAN/INN), 937799-91-2, MLS006010185, SCHEMBL426568, Olaparib, KU-0059436, OLAPARIB [ORANGE BOOK], CHEMBL521686, GTPL7519, BDBM27566, DTXSID60917988, EX-A002, L01XX46, FDLYAMZZIXQODN-UHFFFAOYSA-N, BCPP000360, GLXC-02796, HMS3295I09, HMS3426C03, HMS3654G13, HMS3746K07, HMS3870H03, AMY10295, BCP01872, 763113-22-0, Lynparza,, NSC747856, NSC753686, s1060, AKOS005145764, AC-7939, BCP9000363, CCG-264799, CS-0075, DB09074, EX-7210, NSC-753686, SB14617, SS-4573, AZD2281,Olaparib, KU-0059436, NCGC00238451-01, NCGC00238451-02, NCGC00238451-08, NCGC00238451-09, NCGC00238451-11, 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one, 4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone, 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one, BO164169, HY-10162, SMR004701291, SY040527, A9666, FT-0651458, NS00072449, SW218142-2, D09730, EN300-7542225, J-503540, Q7083106, AZD2281 , KU0059436, BRD-K02113016-001-08-9, BRD-K02113016-001-09-7, Z2227698469, 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine, 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one, 1021843-02-6, 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one

Name	Olaparib
PubChem CID	23725625
Molecular Weight	434.5g/mol
Synonyms	Olaparib, 763113-22-0, AZD2281, Lynparza, AZD-2281, KU-0059436, AZD 2281, 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine, OLAPARIB cpd, 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one, KU-59436, UNII-WOH1JD9AR8, WOH1JD9AR8, Olaparib (AZD-2281), Olaparib (AZD2281, Ku-0059436), Olaparibum, Olaparib [USAN:INN], AZ2281, NSC-747856, AZD221, CHEBI:83766, 4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one, MFCD13185161, AZ-2281, KEYLYNK-010 COMPONENT OLAPARIB, KU59436, KU 59436, 4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One, 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one, NSC 747856, OLAPARIB COMPONENT OF KEYLYNK-010, OLAPARIB (MART.), OLAPARIB [MART.], Olaparib (DISCONTINUED), Olaparib [INN], (2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-, 1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-, 4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one, PIPERAZINE, 1-(CYCLOPROPYLCARBONYL)-4-(5-((3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL)-2-FLUOROBENZOYL)-, Olaparib (AZD2281; Ku-0059436), C24H23FN4O3, Olaparib (AZD2281), 4-(3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one, 4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one, Olaparib- Bio-X, Lynparza (TN), 09L, 1(2H)-PHTHALAZINONE, 4-((3-((4-(CYCLOPROPYLCARBONYL)-1-PIPERAZINYL)CARBONYL)-4-FLUOROPHENYL)METHYL)-, 4-((3-((4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL)CARBONYL)-4-FLUOROPHENYL)METHYL)PHTHALAZIN-1(2H)-ONE, 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one, 4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone; AZD 2281; KU 0059436; KU 59436; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine;, AZD2281(olaparib), OLAPARIB [USAN], OLAPARIB [JAN], OLAPARIB [MI], OLAPARIB [VANDF], OLAPARIB [WHO-DD], AZD-2281 (Olaparib), PARP inhibitor AZD2281, Olaparib (JAN/USAN/INN), 937799-91-2, MLS006010185, SCHEMBL426568, Olaparib, KU-0059436, OLAPARIB [ORANGE BOOK], CHEMBL521686, GTPL7519, BDBM27566, DTXSID60917988, EX-A002, L01XX46, FDLYAMZZIXQODN-UHFFFAOYSA-N, BCPP000360, GLXC-02796, HMS3295I09, HMS3426C03, HMS3654G13, HMS3746K07, HMS3870H03, AMY10295, BCP01872, 763113-22-0, Lynparza,, NSC747856, NSC753686, s1060, AKOS005145764, AC-7939, BCP9000363, CCG-264799, CS-0075, DB09074, EX-7210, NSC-753686, SB14617, SS-4573, AZD2281,Olaparib, KU-0059436, NCGC00238451-01, NCGC00238451-02, NCGC00238451-08, NCGC00238451-09, NCGC00238451-11, 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one, 4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone, 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one, BO164169, HY-10162, SMR004701291, SY040527, A9666, FT-0651458, NS00072449, SW218142-2, D09730, EN300-7542225, J-503540, Q7083106, AZD2281 , KU0059436, BRD-K02113016-001-08-9, BRD-K02113016-001-09-7, Z2227698469, 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine, 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one, 1021843-02-6, 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one
Drug Type	Small molecule
Formula	C₂₄H₂₃FN₄O₃
SMILES	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
InChI	1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
InChIKey	FDLYAMZZIXQODN-UHFFFAOYSA-N
CAS Number	763113-22-0
ChEMBL ID	CHEMBL521686
ChEBI ID	CHEBI:83766
TTD ID	D0J9HW
Drug Bank ID	DB09074
KEGG ID	D09730
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Curcumin, Olaparib
Partner Name	Curcumin
Disease Info	[ICD-11: 2B66.Z]	Oral cancer		Investigative
Biological Phenomena	Inhibition-->Chromatin remodeling
Gene Regulation	Down-regulation	Expression	PARP1	hsa142
	Down-regulation	Expression	CHD1L	hsa9557
	Down-regulation	Expression	H3C1	hsa8350
	Down-regulation	Expression	EP300	hsa2033
In Vitro Model	H357	Tongue squamous cell carcinoma	Homo sapiens (Human)	CVCL_2462
Result	The present study reveals that Cur + Ola treatment increased oral cancer cell death not only through catalytic inhibition of PARP-1 but also predominantly through PARP-1 trapping and indirect inhibition of chromatin remodeling.

Pair Name	Resveratrol, Olaparib
Partner Name	Resveratrol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Down-regulation	Expression	PARP1	hsa142
	Down-regulation	Expression	BRCA1	hsa672
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL-xL	hsa598
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vitro Model	T-47D	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0553
In Vivo Model	Tumor was induced by injecting MCF-7 cells (1 × 107 in 200 μL sterile 1X PBS) on the right breast fat pads of 6–7 weeks old female BALB/c mice. After formation of tumor, the mice were orally treated with RES + OLA combination (40 mg/kg RES and 20 nM/kg OLA per day) for 30 days.
Result	RES + OLA combination treatment enhanced breast cancer cell death by causing excessive DNA damage and also simultaneously inhibiting the HR pathway.

No.	Title	Href
1	Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly. DNA Repair (Amst). 2021 Sep;105:103157. doi: 10.1016/j.dnarep.2021.103157.	`Click`
2	Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway. Exp Cell Res. 2022 Nov 1;420(1):113338. doi: 10.1016/j.yexcr.2022.113338.	`Click`